The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin Lymphoma who were confirmed resistant to Anti-PD-1 antibody therapy.
Hodgkin Lymphoma|Anti-PD-1 Antibody Resistant
DRUG: Chidamide; Decitabine; Camrelizumab|DRUG: Decitabine+Camrelizumab
ORR assess by investigators per the 2014 Lugano classification, rate of subjects achieved objective response in all evaluable subjects, 3 years|Number of Subjects with treatment-related adverse events (AEs), Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0., 3 years
This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin Lymphoma who were confirmed resistant to Anti-PD-1 antibody therapy.